SMA

Most-clicked pharma news for week ending March 25: PTC Therapeutics CEO retires and Novartis' Zolgensma shows sustained efficacy
Most-clicked pharma news for week ending March 25: PTC Therapeutics CEO retires and Novartis' Zolgensma shows sustained efficacy
CP Wire
PTC Therapeutics
Novartis
Zolgensma
SMA
Novo Nordisk
Ozempic
obesity
diabetes
Baxter
M&A
Celltrio
Thermo Fisher
Pfizer
Astellas
Xtandi
NIH
Flag link:
Most-clicked pharma news for week ending March 25: PTC Therapeutics CEO retires and Novartis' Zolgensma shows sustained efficacy
PTC Therapeutics
Novartis
Zolgensma
SMA
Novo Nordisk
Ozempic
obesity
diabetes
Baxter
M&A
Celltrio
Thermo Fisher
Pfizer
Astellas
Xtandi
NIH
Flag link:
Novartis: SMA Drug Zolgensma Long-term Data Shows Sustained Durability Up To 7.5 Years Post-dosing
Novartis: SMA Drug Zolgensma Long-term Data Shows Sustained Durability Up To 7.5 Years Post-dosing
NASDAQ
Novartis
SMA
Zolgensma
gene therapy
Flag link:
EMA weighs new safety guidance for Novartis’ gene therapy Zolgensma
EMA weighs new safety guidance for Novartis’ gene therapy Zolgensma
BioPharma Dive
Novartis
gene therapy
Zolgensma
SMA
Europe
Flag link:
Biogen, scrapping for SMA market share, bets $10M on implant to improve delivery of Spinraza
Biogen, scrapping for SMA market share, bets $10M on implant to improve delivery of Spinraza
Fierce Pharma
Biogen
Alcyone Therapeutics
SMA
Spinraza
devices
Medtech
Flag link:
Novartis sales of Zolgensma gene therapy slow as market shifts
Novartis sales of Zolgensma gene therapy slow as market shifts
BioPharma Dive
Novartis
gene therapy
spinal muscular atrophy
SMA
Zolgensma
Flag link:
Novartis' Zolgensma Under Fire Again as Nature Retracts 2010 Paper
Novartis' Zolgensma Under Fire Again as Nature Retracts 2010 Paper
BioSpace
Novartis
Zolgensma
data manipulation
SMA
Flag link:
Novartis reports deaths of two patients treated with Zolgensma gene therapy
Novartis reports deaths of two patients treated with Zolgensma gene therapy
BioPharma Dive
Novartis
gene therapy
Zolgensma
SMA
patient deaths
spinal muscular atrophy
Flag link:
Intercept, Annovis and Biohaven Advance Late Phase Trials
Intercept, Annovis and Biohaven Advance Late Phase Trials
BioSpace
Intercept Pharma NASH
Annovis
buntanetap
Parkinson's Disease
Biohaven
taldefgrobep alfa
SMA
Flag link:
Roche puts pressure on SMA rivals with new FDA approval
Roche puts pressure on SMA rivals with new FDA approval
Pharmaforum
Roche
PTC Therapeutics
SMA
Evrysdi
FDA
Flag link:
New Three-Year Data for Genentech’s Evrysdi (risdiplam) Show Long-Term Improvements in Survival and Motor Milestones in Babies With Type 1 Spinal Muscular Atrophy (SMA)
New Three-Year Data for Genentech’s Evrysdi (risdiplam) Show Long-Term Improvements in Survival and Motor Milestones in Babies With Type 1 Spinal Muscular Atrophy (SMA)
BioSpace
Genentech
Evrysdi
risdiplam
SMA
spinal muscular atrophy
Flag link:
Biogen Announces New Spinraza Data Ahead of Presentation
Biogen Announces New Spinraza Data Ahead of Presentation
BioSpace
Biogen
Spinraza
SMA
spinal muscular atrophy
Flag link:
Novartis has negotiated Zolgensma access for half of the European SMA population, exec says. How'd it get there?
Novartis has negotiated Zolgensma access for half of the European SMA population, exec says. How'd it get there?
Fierce Pharma
Novartis
Europe
Zolgensma
SMA
spinal muscular atrophy
Flag link:
Zolgensma patent spat brews between Novartis and Regenxbio as top Novartis gene therapy exec departs
Zolgensma patent spat brews between Novartis and Regenxbio as top Novartis gene therapy exec departs
Endpoints
Regenxbio
gene therapy
patents
Novartis
Zolgensma
SMA
Flag link:
Citing 'less-than-optimal' outcomes for Roche's Evrysdi, Biogen launches high-dose Spinraza trial
Citing 'less-than-optimal' outcomes for Roche's Evrysdi, Biogen launches high-dose Spinraza trial
Fierce Pharma
Biogen
Spinraza
SMA
Roche
Evrysdi
spinal muscular atrophy
Flag link:
Novartis to launch new Zolgensma trial after FDA lifts restriction
Novartis to launch new Zolgensma trial after FDA lifts restriction
Reuters
Novartis
Zolgensma
clinical trials
SMA
FDA
Flag link:
Novartis touts latest Zolgensma data as SMA competition against Biogen, Roche heats up
Novartis touts latest Zolgensma data as SMA competition against Biogen, Roche heats up
Fierce Pharma
Novartis
SMA
spinal muscular atrophy
Zolgensma
Roche
Evresdi
Flag link:
Novartis’ $2 Million Gene Therapy Zolgensma Shows ‘Remarkable’ Results and Offers Hope for Children with SMA
Novartis’ $2 Million Gene Therapy Zolgensma Shows ‘Remarkable’ Results and Offers Hope for Children with SMA
Xtalks
Novartis
Zolgensma
SMA
gene therapy
Flag link:
Zolgensma flatlines, but Spinraza isn’t the beneficiary
Zolgensma flatlines, but Spinraza isn’t the beneficiary
EP Vantage
SMA
Biogen
Novartis
Roche
Spinraza
Zolgensma
Evrysdi
Flag link:
Biogen Reports New Spinraza Data in SMA
Biogen Reports New Spinraza Data in SMA
Global Genes
Biogen
Spinraza
SMA
Flag link:

Pages